CDIO: מכפיל P/S Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics (CDIO) leverages AI in epigenetic testing to implement premium pricing, although the price/sales multiple exhibits volatility, currently standing at 278.00. Slow technology adoption by clinics and a liquidity shortage are constraining growth. Business stability is maintained through the optimization of biomaterial logistics and an extensive network of partner laboratories, which minimizes operational risks.

The scaling of cloud capacities at Cardio Diagnostics (CDIO) for continuous genetic analysis directly impacts revenue growth rates, which the market prices in through market capitalization. By analyzing the price-to-sales multiple, an investor correlates the current business value with actual sales volume, eliminating time lags between reports and identifying whether the asset is overvalued relative to its operational efficiency.